FDA Expands Approval of Evinacumab to Treat Ultra-Rare High Cholesterol in Infants as Young as One Year Old
Table of Contents
The U.S.Food and Drug Administration (FDA) has substantially expanded the approved use of evinacumab (evkeeza; Regeneron), a novel therapy for homozygous familial hypercholesterolemia (HoFH), now including children as young as one year old. This approval marks a critical advancement in treating this life-threatening condition,offering hope to families with limited options for managing remarkably high cholesterol levels from birth.
The newest expansion addresses a notable unmet need for the most vulnerable patients, those diagnosed with HoFH in infancy. Clinical data demonstrates evinacumab can reduce low-density lipoprotein cholesterol (LDL-C) by up to 50% compared to placebo in this patient population.
The decision was based on safety and efficacy data from a small cohort of six children with HoFH who participated in expanded access or compassionate use programs. Importantly,no new safety concerns were identified,with the most commonly reported adverse reactions being mild: nasopharyngitis,influenza-like illness,dizziness,rhinorrhea,nausea,and fatigue. These young patients experienced similar robust reductions in LDL-C, confirming the drug’s effectiveness across a wider age range.
Understanding Homozygous familial Hypercholesterolemia
HoFH is a devastating genetic disorder characterized by extremely high levels of LDL-C and a dramatically increased risk of accelerated atherosclerotic cardiovascular disease (ASCVD). Affecting approximately 1,300 people in the U.S. annually, HoFH is far rarer and more severe than the heterozygous form of familial hypercholesterolemia. Patients with HoFH often have LDL-C levels exceeding 400 mg/dL due to a genetic defect impacting their ability to clear cholesterol from the blood.
Without treatment, individuals with HoFH face a significantly elevated risk of cardiac events and premature ASCVD, potentially experiencing complications as early as their teenage years. Unluckily, diagnosis is often delayed, leaving younger patients without access to crucial interventions. “The approval of [evinacumab] for children as young as 1 year of age addresses a critical unmet need,” stated Katherine Wilemon, founder and CEO of the Family Heart Foundation, in a recent release.
Targeting ANGPTL3: A Novel Approach to Cholesterol Management
Evinacumab represents a new class of lipid-lowering therapies.Developed by Regeneron, the medication is a fully human monoclonal antibody designed to block angiopoietin-like 3 (ANGPTL3). Research has shown that individuals with naturally non-functioning ANGPTL3 protein exhibit lower LDL-C levels and a reduced risk of coronary artery disease.
ANGPTL3 regulates circulating lipids by inhibiting lipoprotein lipase and endothelial lipase. By blocking this protein, evinacumab effectively lowers LDL-C, offering a promising new target for cardiovascular prevention. “families and their medical teams will now have an effective treatment option for these very young children,” one official noted, emphasizing the importance of early identification and treatment through pediatric screenings.
The Pharmacist’s Crucial Role in HoFH Management
Pharmacists are poised to play a vital role in the successful implementation of evinacumab therapy. They will be instrumental in counseling parents and guardians about the medication’s benefits and potential risks, ensuring informed decision-making. Communicating potential adverse effects (AEs), while reassuring families that these are typically mild, will be a key component of their responsibilities.
Furthermore, pharmacists must reinforce the importance of continuing existing lipid-lowering therapies (LLTs) alongside evinacumab, coupled with a healthy diet and lifestyle interventions, to maximize treatment efficacy. Research continues to explore evinacumab’s potential in even younger populations, including children under one year of age. Early diagnosis and prompt treatment remain paramount in combating the high LDL-C levels and preventing premature ASCVD associated with HoFH.
